Informational only — Not medical advice. Always consult a licensed healthcare provider.

Community data Updated 23 hours ago

Indications

Vinorelbin is used together with cisplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). It is also used on its own, as a single agent, to treat patients with metastatic NSCLC.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Vinorelbine is a vinca alkaloid that interferes with microtubule assembly. Its antitumor activity is thought to come mainly from stopping mitosis at metaphase, which it does by interacting with tubulin. Vinorelbine may also interfere with 1) amino acid, cyclic AMP and glutathione metabolism, 2) calmodulin-dependent Ca2+ transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis. In intact mouse embryo tectal plates, vinorelbine blocked mitotic microtubule formation at a concentration of 2 µM, and this held cells at metaphase. It caused depolymerization of axonal microtubules only at a concentration of 40 µM, which suggests that vinorelbine has a modest selectivity for mitotic microtubules.

Pregnancy & Breastfeeding

Vinorelbine Tartrate can harm an unborn baby if it is given to a pregnant woman. This is based on animal studies and on how the medicine works. There isn't enough human data to say what the risk is for major birth defects, miscarriage, or other bad outcomes for the mother or the baby. In animal studies, embryo and fetal toxicity were seen in mice and rabbits at vinorelbine doses of about 0.33 and 0.18 times the human therapeutic dose, respectively. Pregnant women should be told about the possible risk to the fetus.

No data exist on whether vinorelbine passes into human milk, or on what it does to a breastfed infant or to milk production. Because it could cause serious adverse reactions in a breastfed infant, women are advised not to breastfeed during treatment with Vinorelbine Tartrate and for 9 days after the final dose.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: In combination with cisplatin 100 mg/m2, the recommended dose of Vinorelbine Tartrate is 25 mg/m2. It is given as an intravenous injection or infusion over 6 to 10 minutes on Days 1, 8, 15 and 22 of a 28-day cycle. The cisplatin 100 mg/m2 is given on Day 1 only of each 28-day cycle. In combination with cisplatin 120 mg/m2, the recommended dose of Vinorelbine Tartrate is 30 mg/m2, given as an intravenous injection or infusion over 6 to 10 minutes once a week. The cisplatin 120 mg/m2 is given on Days 1 and 29, then every 6 weeks. As a single agent, the recommended dose of Vinorelbine Tartrate is 30 mg/m2, given intravenously over 6 to 10 minutes once a week. Pediatric use: the safety and effectiveness of Vinorelbine Tartrate in pediatric patients have not been established.